Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John F Thompson, MD
Sydney Melanoma Unit
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sydney Melanoma Unit
Sydney, New South Wales, Australia
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Royal Adelaide Hospital
Adelaide, South Australia, Australia
- California Pacific Medical Center
San Francisco, California, United States
- University of Louisville
Louisville, Kentucky, United States
- St Luke'S Hospital & Health Network
Bethlehem, Pennsylvania, United States
- M.D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2007
- Primary completion
- 31 May 2010
- Completion
- 30 Jun 2012
- Last update posted
- 25 Aug 2014
- Registered enrollment
- 80
- Registry id
- NCT00521053
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.